一種新型計(jì)算機(jī)輔助檢測(cè)（CAD）系統(tǒng)，是第一種能夠精確輔助放射技師檢測(cè)早期肺癌的系統(tǒng)。根據(jù)美國(guó)癌癥學(xué)會(huì)的說(shuō)法，如果肺癌在比較局限的時(shí)候能夠被檢測(cè)或者治療，患者的5年生存率能夠在第I階段提高495。

這套CAD系統(tǒng)在患者的胸部X線片上檢測(cè)疑似肺部腫塊。然而這套系統(tǒng)并不能夠獨(dú)立鑒別疾病，系統(tǒng)為放射科技師“閱讀”X線圖像、處理信息、展示資料，以幫助檢測(cè)病變。

這套系統(tǒng)叫做RapidScreen，是由Riverain醫(yī)學(xué)公司研制開發(fā)的，在2001年7月獲得了美國(guó)食品藥品管理局的上市銷售以前的批準(zhǔn)。這種技術(shù)是根據(jù)一種能夠檢測(cè)并鑒別87種與單個(gè)肺部腫塊相關(guān)的獨(dú)特信號(hào)的運(yùn)算法則為基礎(chǔ)研制開發(fā)的。在臨床試驗(yàn)中，放射科技師使用RapidScreen能夠?qū)?-14毫米大小的腫瘤鑒別成功率增加23％。

CAD System for Lung Cancer
 
A new computer-aided detection (CAD) system is the first to accurately assist radiologists in detecting early-stage lung cancer. If lung cancer is found and treated while localized, a patient’s five-year survival can increase to 49% at stage I, according to the American Cancer Society.

The CAD system detects suspicious pulmonary nodules on chest x-rays. Whereas it does not identify the disease independently, this system “reads” the x-ray images, processes the information, and displays the data for the radiologist to detect an abnormality.

The system, called RapidScreen, was developed by Riverain Medical
(Miamisburg, OH, USA; www.riverainmedical.com), and received the U.S. Food and Drug Administration (FDA) premarket approval in July 2001. The technology is based on an algorithm to detect and classify 87 exclusive signatures that are associated with solitary pulmonary nodules. In clinical studies, radiologists using RapidScreen improved the identification of tumors between 9-14 mm by 23%.